Researchers from the German Cancer Research Center (DKFZ) have collaborated with the SILVACX project group at Heidelberg University to develop a therapeutic vaccination concept that can mobilize the immune system to target cancer cells. The team showed that virus peptides coupled to silica nanoparticles can elicit effective T-cell responses against HPV-related tumors. In a mouse model, the nanoparticle-based vaccine was able to partially or completely suppress HPV-related tumors.

Summary/Description (1–2 sentences):
An international research team led by MDI Biological Laboratory has discovered that a little-known molecule, heparanase 2 (Hpa2), plays a critical role in maintaining blood vessel integrity. Published in Arteriosclerosis, Thrombosis, and Vascular Biology, the findings suggest Hpa2 may provide a natural mechanism to prevent and treat diseases linked to vascular leakiness, including diabetic retinopathy, macular degeneration, kidney disease, cardiovascular disease, and cancer.

Clinicians typically classify meningiomas — the most common type of brain tumor — into three grades, ranging from slow-growing to aggressive. But a new multi-institutional study suggests that appearances may be deceiving. If a tumor shows activity in a gene called telomerase reverse transcriptase (TERT), it tends to recur more quickly, even if it looks low-grade under the microscope.

Scientists have found a way to stop brain cancer cells spreading by essentially ‘freezing’ a key molecule in the brain.

A first-of-its-kind clinical trial identified risk of breast cancer recurrence and successfully treated dormant tumor cells using existing drugs.

Researchers at the University of Southampton examining worldwide variations in funding for cancer research say there’s a pressing need to invest more in lower income countries.

A randomized controlled trial aimed to determine whether providing information on patient risk for advanced colorectal neoplasia (ACN) to patients and providers affects colorectal cancer (CRC) screening uptake.

CRISPR gene-editing machinery could transform medicine but is difficult to get into tissues and disease-relevant cells. New delivery system loads CRISPR machinery inside spherical nucleic acid (SNA) nanoparticles. Particles entered cells three times more effectively, tripled gene-editing efficiency, and decreased toxicity compared to current delivery methods.